Regulatory approval

Published by the Health Service Executive. Approved

Induction of remission in newly diagnosed, previously untreated adult acute lymphoblastic leukaemia (ALL) patients (aged 25-65 years) treated on UKALL14-protocol.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Imatinib - CDS; other drugs - N/A

Citation

UKALL14 Phase 1 Standard Induction Therapy, 2026, version number 1a, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/7011/874_UKALL14_Phase_1_Standard_Induction_Therapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HSE (1) BCR::ABL1 Acute Lymphoblastic Leukemia Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Vincristine
HSE (1) BCR::ABL1, CD20 + Acute Lymphoblastic Leukemia Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Rituximab, Vincristine
HSE (1) CD20 + Acute Lymphoblastic Leukemia Daunorubicin, Dexamethasone, Methotrexate, Rituximab, Vincristine

Contributions

Date Contributor Description
2026-08-02 Van Allen lab Initial curation of into moalmanac-db
2025-10-01 Health Service Executive Indication approved for reimbursement.